[(2R)-1-[(2R)-2-benzamidopropanoyl]pyrrolidin-2-yl]boronic acid | 1431976-79-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(2R)-1-[(2R)-2-benzamidopropanoyl]pyrrolidin-2-yl]boronic acid
• CAS: 1431976-79-2
• 化学式: C₁₄H₁₉BN₂O₄
• 分子量: 290.127
• InChiKey: JBEIDHHJQWKELT-PWSUYJOCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.19
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  89.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (2R)-2-amino-1-[(2R)-2-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]pyrrolidin-1-yl]propan-1-one 、 苯甲酰氯 在 N,N-二异丙基乙胺 、 三氯化硼 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 [(2R)-1-[(2R)-2-benzamidopropanoyl]pyrrolidin-2-yl]boronic acid
  参考文献：
  名称：

  Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase

  摘要：

  Fibroblast activation protein (FAP) is a serine protease selectively expressed on reactive stromal fibroblasts of epithelial carcinomas. It is widely believed to play a role in tumor invasion and metastasis and therefore to represent a potential new drug target for cancer. Investigation into its biological function, however, has been hampered by the current unavailability of selective inhibitors. The challenge has been in identifying inhibitors that are selective for PAP over both the dipeptidyl peptidases (DPPs), with which it shares exopeptidase specificity, and prolyl oligopeptidase (PREP), with which it shares endopeptidase specificity. Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-D-Ala-boroPro (ARI-3099, 6). We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22). Both are boronic acid based inhibitors, demonstrating that high selectivity can be achieved using this electrophile. The inhibitors are stable, easy to synthesize, and should prove to be useful in helping to elucidate the biological functions of these two unique and interesting enzymes, as well as their potential as drug targets.

  DOI：

  10.1021/jm400351a